CERENOME, INC.
Close on Oct 19, 2026
- Market cap
- $11.38M
- P/E (TTM)
- –
- Dividend yield
- –
About Cerenome
Surgical & Medical Instruments & Apparatus, SIC 3841
Plus Therapeutics, Inc. is a United States healthcare company focused on the development and commercialization of precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its clinical-stage pipeline features targeted radiopharmaceuticals intended to deliver radiation therapy directly to tumors, along with diagnostic solutions such as the CNSide platform and test designed for cerebrospinal fluid tumor cell enumeration, immunocytochemistry, fluorescence in situ hybridization, and next-generation sequencing. The company serves the medical and oncology sectors, targeting patients suffering from difficult-to-treat central nervous system cancers and conditions including leptomeningeal metastases.
The company operates within the United States, maintaining corporate facilities and conducting its core clinical and operational activities domestically. Its principal executive offices and headquarters are located in Houston, Texas. Beyond its domestic presence, the provided text does not report any international facilities, clinical sites, or physical retail locations.
Summary of the business section of Cerenome's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CERENOME, INC.
- Founded
- 1996
- Headquarters
- Houston, TX
- Address
- 6420 Levit Green Boulevard, Suite 310 77021
- Phone
- (737) 255-7194
- Website
- plustherapeutics.com
- Employees
- 28, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA P.C., Austin, Texas
Stock & identifiers
- Ticker
- CNSY
- Exchange
- Nasdaq
- IPO date
- Jul 11, 2001
- Shares outstanding
- 8M, Aug 5, 2026
- Public float
- $31.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Apr 2, 2026; 1-for-25 reverse, Apr 1, 2026; 1-for-15 reverse, Aug 14, 2023; 1-for-15 reverse, May 1, 2023; 1-for-50 reverse, Aug 6, 2019; 1-for-50 reverse, Aug 5, 2019; 1-for-10 reverse, May 24, 2018; 1-for-10 reverse, May 23, 2018; 1-for-15 reverse, May 12, 2016; 1-for-15 reverse, May 10, 2016
- SEC CIK
- 1095981
- CUSIP
- 72941H806
- ISIN
- US72941H8060
- LEI
- 549300XD2PHUC73HMY31
- EIN
- 33-0827593
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marc H. Hedrick | Chief Executive Officer, Director | 89,275 |
| Andrew John Hugh MacIntyre Sims | Chief Financial Officer | 8,489 |
| Eric Joseph Daniels | Chief Development Officer | 0 |
| Howard Clowes | Director | 1,981 |
| Es-Johansson An van | Director | 922 |
| Ronald Asbury Andrews | Director | 922 |
| Richard J. Hawkins | Director | 1,529 |
| Kyle Guse | Director | 922 |
| Robert P. Lenk | Director | 139,327 |
| Greg Petersen | Director | 48,921 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Marc H. Hedrick, M.D | $5.57M | $4.73M | $1.63M | $11 | – |
| FY2024 Marc H. Hedrick, M.D | $1.26M | $1.64M | $907.03K | $24 | – |
| FY2023 Marc H. Hedrick, M.D | $1.13M | $1.57M | $1.21M | $37 | – |
| FY2022 Marc H. Hendrick, M.D. | $954.65K | $1.64M | $1.08M | $30 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 28 full-time employees.”
Corporate history
Events identified from SEC filings